
    
      Randomized, double blind, placebo controlled, prospective trial in patients, receiving a
      kidney transplantation. Patients will be randomized to receive either Epoetin Beta
      (Neorecormon; Roche) or placebo.

      The primary endpoint will be delayed graft function. The anticipated duration of this trial
      is 2 year and the target sample size is 60 patients per arm.
    
  